<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01280175</url>
  </required_header>
  <id_info>
    <org_study_id>FB/PS/14/163/06</org_study_id>
    <nct_id>NCT01280175</nct_id>
  </id_info>
  <brief_title>Foster With or Without Charcoal Block or Aerochamber Plus</brief_title>
  <official_title>Pharmacokinetics and Lung Bioavailability of BDP/Formoterol HFA Fixed Combination After Single Administration in 12 Healthy Volunteers Using the Standard Actuator With or Without Charcoal Block or the Aerochamber Spacer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cross Research S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the systemic exposure of BDP, its metabolite&#xD;
      beclomethasone 17-monopropionate (B17MP) and formoterol after inhalation of BDP/Formoterol&#xD;
      100/6 µg pMDI combination (CHF1535) using the standard actuator and charcoal block technique&#xD;
      or using a Spacer (AeroChamber Plus, Trudell) in comparison with inhalation using the&#xD;
      standard actuator&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic exposure and lung bioavailability of BDP, B17MP and formoterol.</measure>
    <time_frame>from pre-dose until 12 h post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>General tolerability and safety of the test product.</measure>
    <time_frame>from pre-dose until 12 h post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>pMDI + charcoal block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BDP/formoterol 100/6 µg pMDI with charcoal ingestion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pMDI + Aerochamber Plus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BDP/formoterol 100/6 µg with Aerochamber Plus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pMDI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BDP/formoterol 100/g µg pMDI</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>charcoal block</intervention_name>
    <arm_group_label>pMDI + charcoal block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aerochamber Plus spacer</intervention_name>
    <arm_group_label>pMDI + Aerochamber Plus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pMDI standard actuator</intervention_name>
    <arm_group_label>pMDI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sex: male&#xD;
&#xD;
          -  18≤age≤45 years old&#xD;
&#xD;
          -  BMI: 18≤BMI≤28 kg/m2&#xD;
&#xD;
          -  Non-smokers&#xD;
&#xD;
          -  Vital signs: SBP 100-139 mmHg, DBP 50-89, HR 50-90 bpm, measured after 5 min of rest&#xD;
             in the sitting position&#xD;
&#xD;
          -  Full comprehension: ability to use correctly the pMDI preparations; ability to&#xD;
             comprehend the full nature and purpose of the study, including possible risks and side&#xD;
             effects; ability to co-operate with the Investigator and to comply with the&#xD;
             requirements of the entire study&#xD;
&#xD;
          -  Informed Consent: signed written informed consent prior to inclusion in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ECG (12 leads): clinically relevant abnormalities and/or QTc &gt;450 msec;&#xD;
&#xD;
          -  Physical findings: clinically relevant abnormal physical findings, which could&#xD;
             interfere with the objectives of the study; in particular any abnormality in the lung&#xD;
             functionality: FEV1 &lt;80% predicted values according to European Respiratory Society&#xD;
             basing upon Quanjer et al. (25)&#xD;
&#xD;
          -  Laboratory analyses: clinically relevant abnormal laboratory values indicative of&#xD;
             physical illness; in particular positive HIV1 and HIV2 serology and/or positive&#xD;
             hepatitis serology indicating acute or chronic hepatitis B or C&#xD;
&#xD;
          -  Allergy: ascertained or presumptive hypersensitivity to the active principles and/or&#xD;
             formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in&#xD;
             general, which the Investigator considers may affect the outcome of the study&#xD;
&#xD;
          -  Diseases: relevant history of renal, hepatic, gastrointestinal, cardiovascular,&#xD;
             respiratory, skin, haematological, endocrine or neurological diseases, that may&#xD;
             interfere with the aim of the study&#xD;
&#xD;
          -  Medications: medication, including OTC, during 2 weeks before the start of the study.&#xD;
             Any known enzyme inducing drug or enzyme inhibitor must be stopped at least 2 months&#xD;
             before study start&#xD;
&#xD;
          -  Investigative drug trials: participation in the evaluation of any drug within 3 months&#xD;
             prior to the screening&#xD;
&#xD;
          -  Blood donation: blood donations during the 3 months prior to this study&#xD;
&#xD;
          -  Drug, alcohol, caffeine, tobacco: history of drug, alcohol [&gt;2 drinks/day, defined&#xD;
             according to USDA Dietary Guidelines 2005 (26)], caffeine (&gt;5 cups coffee/tea/day)&#xD;
             abuse or smoking&#xD;
&#xD;
          -  Abnormal diets (&lt;1600 or &gt;3500 kcal/day) or substantial changes in eating habits&#xD;
             within the past 4 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Rusca, MD, FMH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CROSS Research SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CROSS Research SA</name>
      <address>
        <city>Arzo</city>
        <state>Via F.A. Giorgioli, 14</state>
        <zip>6864</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Singh D, Collarini S, Poli G, Acerbi D, Amadasi A, Rusca A. Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. Br J Clin Pharmacol. 2011 Dec;72(6):932-9. doi: 10.1111/j.1365-2125.2011.04024.x.</citation>
    <PMID>21615456</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 17, 2011</study_first_submitted>
  <study_first_submitted_qc>January 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2011</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <name_title>Sara Collarini / Clinical Study Manager</name_title>
    <organization>Chiesi Farmaceutici</organization>
  </responsible_party>
  <keyword>BDP</keyword>
  <keyword>Formoterol</keyword>
  <keyword>pMDI</keyword>
  <keyword>Aerochamber Plus</keyword>
  <keyword>Charcoal</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

